Abstract
Background/Aims
Finding differences in systemic inflammatory response in ulcerative colitis (UC), UC with Clostridium difficile infection (CDI), and CDI could lead to a better ability to differentiate between UC with symptomatic CDI and UC with C. difficile colonization, and could identify specific inflammatory pathways for UC or CDI, which could be therapeutic targets.
Methods
We prospectively collected sera from symptomatic UC patients whose stools were tested for toxigenic C. difficile, and from CDI patients who did not have UC (CDI-noUC). The UC patients with positive tests (UC-CDI) were further categorized into responders to CDI treatment (UC-CDI-R) and non-responders (UC-CDI-NR). We compared serum inflammatory mediators among groups using unadjusted and adjusted multivariable statistics.
Results
We included 117 UC [27 UC-CDI, 90 UC without CDI (UC-noCDI)] and 16 CDI-noUC patients. Principal component analysis (PCA) did not reveal significant differences either between UC-CDI and UC-noCDI groups, or between UC-CDI-R and UC-CDI-NR groups. In contrast, the PCA showed significant separation between the UC and CDI-noUC groups (P = 0.002). In these two groups, hepatocyte growth factor (HGF) and chemokine (C-C motif) ligand 2 (CCL2) levels were significantly lower and IL-23 levels were higher in UC patients in multivariable analyses. The model to distinguish UC from CDI including IL-23, HGF, CCL2, age, gender, and HGB had an AuROC of 0.93.
Conclusion
Inflammatory profiles could not distinguish UC-CDI from UC-noCDI, and UC-CDI-R from UC-CDI-NR. However, the UC and CDI-noUC groups were significantly different. Future work should examine whether therapeutic agents inhibiting IL-23 or stimulating HGF can treat UC.
Similar content being viewed by others
References
Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA. 2015;313:398–408.
Abraham C, Dulai PS, Vermeire S, Sandborn WJ. Lessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseases. Gastroenterology. 2017;152:374–388.
Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329–342.
Rao K, Erb-Downward JR, Walk ST, et al. The systemic inflammatory response to Clostridium difficile infection. PLoS ONE. 2014;9:e92578.
Olson A, Diebel LN, Liberati DM. Exogenous phosphatidylcholine supplementation improves intestinal barrier defense against Clostridium difficile toxin. J Trauma Acute Care Surg. 2014;77:570–575. (discussion 576).
Brito GA, Sullivan GW, Ciesla WP Jr, Carper HT, Mandell GL, Guerrant RL. Clostridium difficile toxin A alters in vitro-adherent neutrophil morphology and function. J Infect Dis. 2002;185:1297–1306.
Klapproth JM, Sasaki M. Bacterial induction of proinflammatory cytokines in inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:2173–2179.
Connelly TM, Koltun WA, Sangster W, et al. An interleukin-4 polymorphism is associated with susceptibility to Clostridium difficile infection in patients with inflammatory bowel disease: results of a retrospective cohort study. Surgery. 2014;156:769–774.
Steiner TS, Flores CA, Pizarro TT, Guerrant RL. Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. Clin Diagn Lab Immunol. 1997;4:719–722.
Jiang ZD, Garey KW, Price M, et al. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol. 2007;5:964–968.
Sadighi Akha AA, McDermott AJ, Theriot CM, et al. Interleukin-22 and CD160 play additive roles in the host mucosal response to Clostridium difficile infection in mice. Immunology. 2015;144:587–597.
Cowardin CA, Kuehne SA, Buonomo EL, Marie CS, Minton NP, Petri WA Jr. Inflammasome activation contributes to interleukin-23 production in response to Clostridium difficile. MBio. 2015;6:e02386-14.
Buonomo EL, Madan R, Pramoonjago P, Li L, Okusa MD, Petri WA Jr. Role of interleukin 23 signaling in Clostridium difficile colitis. J Infect Dis. 2013;208:917–920.
El Feghaly RE, Stauber JL, Deych E, Gonzalez C, Tarr PI, Haslam DB. Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis. 2013;56:1713–1721.
vegan: Community ecology package (2018). Available at https://CRAN.R-project.org/package=vegan.
Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1–22.
Olsen T, Goll R, Cui G, et al. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol. 2007;42:1312–1320.
Reimund JM, Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn’s disease. J Clin Immunol. 1996;16:144–150.
West GA, Matsuura T, Levine AD, Klein JS, Fiocchi C. Interleukin 4 in inflammatory bowel disease and mucosal immune reactivity. Gastroenterology. 1996;110:1683–1695.
Czepiel J, Biesiada G, Brzozowski T, et al. The role of local and systemic cytokines in patients infected with Clostridium difficile. J Physiol Pharmacol. 2014;65:695–703.
Tahara Y, Ido A, Yamamoto S, et al. Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats. J Pharmacol Exp Ther. 2003;307:146–151.
Srivastava M, Zurakowski D, Cheifetz P, Leichtner A, Bousvaros A. Elevated serum hepatocyte growth factor in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33:548–553.
Sturm A, Schulte C, Schatton R, et al. Transforming growth factor-beta and hepatocyte growth factor plasma levels in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12:445–450.
Sorour AE, Lonn J, Nakka SS, Nayeri T, Nayeri F. Evaluation of hepatocyte growth factor as a local acute phase response marker in the bowel: the clinical impact of a rapid diagnostic test for immediate identification of acute bowel inflammation. Cytokine. 2015;71:8–15.
McCormack G, Moriarty D, O’Donoghue DP, McCormick PA, Sheahan K, Baird AW. Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res. 2001;50:491–495.
Kim JM, Kim JS, Jun HC, Oh YK, Song IS, Kim CY. Differential expression and polarized secretion of CXC and CC chemokines by human intestinal epithelial cancer cell lines in response to Clostridium difficile toxin A. Microbiol Immunol. 2002;46:333–342.
Mohammadi M, Hayatbakhsh MM, Zahedi MJ, Jalalpour MR, Pakgohar A. Serum interleukin-23 levels in patients with ulcerative colitis. Iran J Immunol.. 2011;8:183–188.
Mirsattari D, Seyyedmajidi M, Zojaji H, et al. The relation between the level of interleukin-23 with duration and severity of ulcerative colitis. Gastroenterol Hepatol Bed Bench. 2012;5:49–53.
Zheng ZD, Wan XQ, Liu LY. Serum contents of IL-23 and IL-17 in the patients with ulcerative colitis and the clinical significance. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2011;27:203–206.
Peng LL, Wang Y, Zhu FL, Xu WD, Ji XL, Ni J. IL-23R mutation is associated with ulcerative colitis: a systemic review and meta-analysis. Oncotarget. 2017;8:4849–4863.
Liu M, Zhu W, Wang J, et al. Interleukin-23 receptor genetic polymorphisms and ulcerative colitis susceptibility: a meta-analysis. Clin Res Hepatol Gastroenterol. 2015;39:516–525.
Rao K, Higgins PD. Epidemiology, diagnosis, and management of Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1744–1754.
Author’s contribution
PDRH and KR were involved in study concept and design; JL, LJ, AR, and EB acquired data; JL, KR, and PDRH analyzed and interpreted the data; JL and KR drafted the manuscript; RWS, SMG, AKW, AR, and PDRH critically revised the manuscript for important intellectual content; PDRH was involved in study supervision.
Funding
This work was supported by the following grants. JL: Anandamahidol Foundation, Thailand. KR: the Claude D. Pepper Older Americans Independence Center [Grant Number AG-024824] and the Michigan Institute for Clinical and Health Research [Grant Number 2UL1TR000433]. PDRH: NIH R01 DK109032, R01 GM097117, and R21 AI122098. AKW: a Career Development Award (CDA 11-217) from the United States (U.S.) Department of Veterans Affairs Health Services Research and Development Service. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors report no conflicts.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Limsrivilai, J., Rao, K., Stidham, R.W. et al. Systemic Inflammatory Responses in Ulcerative Colitis Patients and Clostridium difficile Infection. Dig Dis Sci 63, 1801–1810 (2018). https://doi.org/10.1007/s10620-018-5044-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-018-5044-1